Citations

Clear

2303 citation(s) found for "Yu, Edward".

The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)
Azhari, Hassan, King, James A. , Mak, Joyce W.Y., Ben‐Horin, Shomron , Loftus, Edward V. , Burisch, Johan , Lakatos, Péter L. , Padilla, Francisco Javier Bosques, Underwood, Fox E., Kaplan, Gilaad G , Loftus, Edward V , King, James , Lakatos, Peter L , Coward, Stephanie B. , Windsor, Joseph W. , Ma, Christopher , Shah, Shailja C. , Ng, Siew C. , Mak, Joyce Wing Yan , Kotze, Paulo Gustavo , Lees, Charlie W. , Gearry, Richard B. , Calvet, Xavier , Kaplan, Gilaad G.

Mayo Clinic

American Journal of Gastroenterology | June 2, 2022 | Volume: 117 | Issue: 9 | Pages: 1419-1427

10.14309/ajg.0000000000001843 | PMID 35973143 Get It

INTRODUCTION: Peptic ulcer disease (PUD) is a common cause of hospitalization worldwide. We assessed temporal trends in hospitalization for PUD in 36 Organisation for Economic Co-operation and Development (OECD) countries since the turn of the 21st century. METHODS: The OECD database contains data on PUD-related hospital discharges and mortality for 36 countries between 2000 and 2019. Hospitalization rates for PUD were expressed as annual rates per 100,000 persons. Joinpoint regression models were used to calculate the average annual percent change (AAPC) with 95% confidence intervals (CIs) for each country, which were pooled using meta-analyses. The incidence of PUD was forecasted to 2021 using autoregressive integrated moving average and Poisson regression models. RESULTS: The overall median hospitalization rate was 42.4 with an interquartile range of 29.7–60.6 per 100,000 person-years. On average, hospitalization rates (AAPC = −3.9%; 95% CI: −4.4, −3.3) and morality rates (AAPC = −4.7%; 95% CI: −5.6, −3.8) for PUD have decreased from 2000 to 2019 globally. The forecasted incidence of PUD hospitalizations in 2021 ranged from 3.5 per 100,000 in Mexico to 92.1 per 100,000 in Lithuania. Across 36 countries in the OECD, 329,000 people are estimated to be hospitalized for PUD in 2021. DISCUSSION: PUD remains an important cause of hospitalization worldwide. Reassuringly, hospitalizations and mortality for PUD have consistently been falling in OECD countries in North America, Latin America, Europe, Asia, and Oceania. Identifying underlying factors driving these trends is essential to sustaining this downward momentum.
High prevalence of fluoroquinolone‐resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018–2020
Faine, Brett , Vakkalanka, J. Priyanka , Gross, Alan E. , Brown, Caitlin S. , Harding, Stephanie J. , Slocum, Giles W. , Zimmerman, David E. , Zepeski, Anne , Rewitzer, Stacey , Howington, Gavin T. , Campbell, Matthew J. , Dawson, Jordan, Treu, Cierra N. , Nelson, Lucas , Jones, Mandy , Flack, Tara , Porter, Blake , Sarangarm, Preeyaporn , Mattson, Alicia E , Bailey, Abby M. , Kelly, Gregory , Talan, David A. , Faine, Brett A , Gross, Alan , Zimmerman, David , Zepeski, Anne , Campbell, Matt , Treu, Cierra N , Talan, David A , Vakkalanka, Priyanka , Rech, Megan A. , Jones, Mandy

Mayo Clinic

Academic Emergency Medicine | June 2, 2022 | Volume: 29 | Issue: 9 | Pages: 1096-1105

10.1111/acem.14545 | PMID 35652493 Get It

AbstractBackgroundUropathogen resistance, fluoroquinolone‐resistance (FQR), and extended spectrum beta‐lactamase (ESBL), has been observed to be emerging worldwide with prevalences above recommended thresholds for routine empirical treatment. The primary aim of our study was to determine the prevalence of FQR from a geographically diverse sample of United States emergency departments (EDs).MethodsWe conducted a multi‐center, observational cohort study using a network of 15 geographically diverse US EDs. All patients ≥18 years of age with the primary or secondary diagnosis of urinary tract infection (UTI) in the ED identified using International Classification of Diseases (ICD‐10) diagnosis code of cystitis, pyelonephritis, or UTI from 2018 to 2020 were included. We calculated descriptive statistics for uropathogens and susceptibilities. Logistic regression analysis was used to identify antimicrobial resistance risk factors associated with FQR Escherichia coli.ResultsAmong 3779 patients who met inclusion criteria, median age was 62.9 years (interquartile range [IQR]: 41–77.6) and 76.3% were female. The most common diagnoses were complicated (41.2%) and uncomplicated cystitis (40.3%). E. coli was the most common pathogen (63.2%), followed by Klebsiella pneumoniae (13.2%) and Enterococcus species (5.8%). Across all sites, overall E. coli FQ‐resistance prevalence was 22.1%, ranging from 10.5 to 29.7% by site. The prevalence of ESBL‐producing uropathogen was 7.4%, ranging from 3.6% to 11.6% by site. Previous IV or oral antimicrobial use in the past 90‐days and history of a multi‐drug resistant pathogen were associated with FQ‐resistant E. coli (odds ratio [OR] 2.68, 95% confidence interval [CI]: 2.04–3.51, and OR 6.93, 95% CI: 4.95–9.70, respectively). Of the patients who had FQ‐resistant E. coli or an ESBL‐producing uropathogen isolated, 116 (37.1%) and 61 (36.7%) did not have any documented risk factors for resistance.ConclusionFQ‐resistant E. coli is widely prevalent across US sites highlighting the need for ongoing monitoring of antimicrobial resistance and, at some locations, modification of empirical treatments.
Durotaxis in Lung Fibrosis: Transitioning from In Vitro Mechanisms to In Vivo Imaging
Ganzleben, I., Chrysovergi, Maria-Anna , Al-Hilal, T.A., Liu, F., Santos, Ana , Vincent, Lauren, Happe, Cassandra, Yates, Charles R. , Mempel, Thorsten R. , Engler, Anne-Marie, Tschumperlin, Daniel J. , Chaum, Edward , Engler, A.J., Lagares, David

Mayo Clinic

A60. PULMONARY FIBROSIS: ANIMAL AND CELL CULTURE MODELS | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5551-A5551

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5551 Get It

Impact of β-blockers on Survival Outcomes in Patients with Unresectable Hepatocellular Carcinoma
Altshuler, Ellery , Kallumkal, Govind, Gao, Hanzhi, Wilson, Jake, Ouni, A. El , Leo, Edward De , Hanayneh, Wissam , Pan, Kelsey , Ouni, Ahmed, Aryan, Mahmoud , Ouni, Ahmed

Mayo Clinic

Hepatic Oncology | May 24, 2022 | Volume: 9 | Issue: 2 | Pages: No page available

10.2217/hep-2021-0010 | PMID 35665305 Get It

Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study
Drawz, Paul E. , Kaur, Nayanjot , Lenoir, Kristin M. , Suarez, Maritza , Powell, J.R., Raj, Dominic S. , Agarwal, Anil , Soman, Sandeep, Whelton, Paul K. , Rahbari-Oskoui, Frederic F. , Dobre, Mirela , Parkulo, Mark A. , Rocco, Michael V. , McWilliams, Andrew , Dwyer, Jamie P. , Thomas, George , Oparil, Suzanne , Horwitz, Edward , Ishani, Areef , Rai, Nayanjot Kaur , Lenoir, Kristin Macfarlane , Agarwal, Anil K , Dobre, Mirela , Parkulo, Mark A , Rocco, Michael V , McWilliams, Andrew , Dwyer, Jamie P , Oparil, Suzanne , Pajewski, Nicholas M , Ishani, Areef , Drawz, Paul , Rahbari-Oskoui, Frederic F , Powell, James R., Beddhu, Srinivasan , Lash, James P. , Rahman, Mahboob , Pajewski, Nicholas M.

Mayo Clinic

Kidney360 | May 23, 2022 | Volume: 3 | Issue: 7 | Pages: 1253-1262

10.34067/kid.0001572022 | PMID 35919535 Get It

Key Points Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control. Creatinine-based ascertainment of AKI, enabled by electronic health record data, may be more sensitive and less biased than traditional serious adverse event adjudication. Background Adjudication of inpatient AKI in the Systolic Blood Pressure Intervention Trial (SPRINT) was based on billing codes and admission and discharge notes. The purpose of this study was to evaluate the effect of intensive versus standard BP control on creatinine-based inpatient and outpatient AKI, and whether AKI was associated with cardiovascular disease (CVD) and mortality. Methods We linked electronic health record (EHR) data from 47 clinic sites with trial data to enable creatinine-based adjudication of AKI. Cox regression was used to evaluate the effect of intensive BP control on the incidence of AKI, and the relationship between incident AKI and CVD and all-cause mortality. Results A total of 3644 participants had linked EHR data. A greater number of inpatient AKI events were identified using EHR data (187 on intensive versus 155 on standard treatment) as compared with serious adverse event (SAE) adjudication in the trial (95 on intensive versus 61 on standard treatment). Intensive treatment increased risk for SPRINT-adjudicated inpatient AKI (HR, 1.51; 95% CI, 1.09 to 2.08) and for creatinine-based outpatient AKI (HR, 1.40; 95% CI, 1.15 to 1.70), but not for creatinine-based inpatient AKI (HR, 1.20; 95% CI, 0.97 to 1.48). Irrespective of the definition (SAE or creatinine based), AKI was associated with increased risk for all-cause mortality, but only creatinine-based inpatient AKI was associated with increased risk for CVD. Conclusions Creatinine-based ascertainment of AKI, enabled by EHR data, may be more sensitive and less biased than traditional SAE adjudication. Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control.
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging
Molinari, Luca , Smith, A.J. Conrad , Landsittel, Douglas , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Investigators, ProCESS and ProGReSS-AKI, Keener, Christopher, Lucko, Nicole, Pike, Francis, Yende, Sachin , Gimbel, Elizabeth, Landis, Kyle, Stapleton, Diana K., Weissfeld, Lisa A., Willochell, Michael, Wofford, Kourtney A., Watts, Hannah , Venkat, Arvind , Hou, Peter C. , Massaro, Anthony F., Parmar, Siddharth , Brewer, Kori L. , Delbridge, Theodore R. , Mainhart, Allison, Miner, James R. , Allen, Todd L., Grissom, Colin K. , Swadron, Stuart P., Carlson, Richard, LoVecchio, Frank , Parry, Blair A. , Ellender, Timothy J., Sama, Andrew E., Fine, Jonathan , Nafeei, Soheil, Wojnar, Margaret, Pearl, Ronald G. , Wilber, Scott T., Sinert, Richard , Orban, David J., Ufberg, Jacob W. , Albertson, Timothy, Panacek, Edward A., Parekh, Sohan, Gunn, Scott R. , Rittenberger, Jon S., Wadas, Richard J. , Edwards, Andrew R., Holmes, T., Weinert, Craig , Harris, Estelle S. , Self, Wesley H. , Dubinski, Diane, Phillips, Carolyn, Migues, Ronald M., Singbartl, Kai , Kellum, John A , Rio‐Pertuz, Gaspar Del , Palevsky, Paul M. , Chawla, Lakhmir S. , Huang, David T. , Angus, Derek C. , Investigators, ProCESS and ProGReSS-AKI, Barnato, Amber E. , Eaton, Tammy L. , Kulstad, Erik Benjamin , Limkakeng, Alexander T. , Conrad, Steven A. , Bajwa, Ednan K. , Filbin, Michael R. , Terndrup, Thomas E. , Wilson, Jason W. , Kelly, Matthew, Wang, Henry E. , McCurdy, Michael T. , Phillips, Carolyn A

Mayo Clinic

JAMA Network Open | May 18, 2022 | Volume: 5 | Issue: 5 | Pages: e2212709

10.1001/jamanetworkopen.2022.12709 | PMID 35583867 Get It

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*
Spiegler, Peter, Wesson, Russell , Weldon, Elaina , Dieter, Rebecca A., Quinn, Max M., Mattoo, Aprajita , Soomro, Irfana, Leung, Sherry , Deterville, Cecilia L., Landrum, B. Mark, Ali, Muhammad Imran, Cohen, David J. , Singer, Andrew L., Sen, Ayan , Lonze, Bonnie E. , Alachkar, Nada , Petkova, Eva , Dieter, Rebecca A. , Li, Yi , Cohen, Steven M. , Ali, Muhammad Imran, Chong, Edward, Hochman, Judith S. , Troxel, Andrea B. , Montgomery, Robert A.

Mayo Clinic

Critical Care Medicine | May 18, 2022 | Volume: 50 | Issue: 9 | Pages: 1348-1359

10.1097/ccm.0000000000005591 | PMID 35583232 Get It

OBJECTIVES: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation. DESIGN: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial. SETTING: Five U.S. medical centers. PATIENTS: Adults inpatients with severe COVID-19 disease and hyperinflammation. INTERVENTIONS: Eighty-one patients enrolled in phase II, randomized 1:1:1 to low-dose (12.5 mg) or high-dose (25 mg) clazakizumab or placebo. Ninety-seven patients enrolled in phase III, randomized 1:1 to high-dose clazakizumab or placebo. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day ventilator-free survival. Secondary outcomes included overall survival, frequency and duration of intubation, and frequency and duration of ICU admission. Per Data Safety and Monitoring Board recommendations, additional secondary outcomes describing clinical status and status changes, as measured by an ordinal scale, were added. Bayesian cumulative proportional odds, logistic, and Poisson regression models were used. The low-dose arm was dropped when the phase II study suggested superiority of the high-dose arm. We report on 152 patients, 74 randomized to placebo and 78 to high-dose clazakizumab. Patients receiving clazakizumab had greater odds of 28-day ventilator-free survival (odds ratio [OR] = 3.84; p [OR > 1] 99.9%), as well as overall survival at 28 and 60 days (OR = 1.75; p [OR > 1] 86.5% and OR = 2.53; p [OR > 1] 97.7%). Clazakizumab was associated with lower odds of intubation (OR = 0.2; p [OR] < 1; 99.9%) and ICU admission (OR = 0.26; p [OR < 1] 99.6%); shorter durations of ventilation and ICU stay (risk ratio [RR] < 0.75; p [RR < 1] > 99% for both); and greater odds of improved clinical status at 14, 28, and 60 days (OR = 2.32, p [OR > 1] 98.1%; OR = 3.36, p [OR > 1] 99.6%; and OR = 3.52, p [OR > 1] 99.8%, respectively). CONCLUSIONS: Clazakizumab significantly improved 28-day ventilator-free survival, 28- and 60-day overall survival, as well as clinical outcomes in hospitalized patients with COVID-19 and hyperinflammation.
Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Hart, Ailsa , D’Haens, Geert , Bereswill, Mareike, Finney‐Hayward, Tricia , Kalabic, Jasmina , Levy, Gweneth, Liang, Huifang , Seow, Cynthia H. , Loftus, Edward V. , Reinisch, Walter, Satsangi, Jack , Loftus, Edward V , Panaccione, Remo , Reinisch, Walter

Mayo Clinic

United European Gastroenterology Journal | May 13, 2022 | Volume: 10 | Issue: 5 | Pages: 485-495

10.1002/ueg2.12236 | PMID 35560533 Get It

AbstractBackgroundPYRAMID was an international post‐marketing registry that aimed to collect data on the long‐term safety and effectiveness of adalimumab treatment per local standard of care in patients with moderately to severely active Crohn's disease (CD). Here, we present post hoc analyses of observational data from patients who became pregnant while participating in this registry and receiving adalimumab.MethodsFrom the subpopulation of patients receiving adalimumab who became pregnant while taking part in PYRAMID, data on patient characteristics, pregnancy outcomes, and complications of pregnancy were analysed retrospectively.ResultsAcross the PYRAMID registry, 293 pregnancies occurred in patients who had gestational adalimumab exposure (average disease duration at last menstrual period: 8.6 years), resulting in 300 pregnancy outcomes. A total of 197 pregnancies (67.2%) were exposed to adalimumab in all trimesters per physician's decision. Of the known reported outcomes (96.3%), 81.7% (236/289) were live births, 10.4% (30/289) were spontaneous abortions, 4.8% (14/289) elective terminations, 2.8% (8/289) ectopic pregnancies, and 0.3% (1/289) was a stillbirth. Congenital malformations (pulmonary valve stenosis and tricuspid valve incompetence) were reported in one infant. In addition to the pregnancy outcomes described above, 23 complications of pregnancy were reported in 20 patients.ConclusionsThis analysis showed that adalimumab treatment in patients with CD, who became pregnant whilst participating in the PYRAMID registry, contributed no additional adverse effects during the pregnancy course or on pregnancy outcomes.
Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles
Eekhoff, Elisabeth M. W. , Ruiter, Ruben D. de , Smilde, Bernard J. , Schoenmaker, Ton , Netelenbos, Coen , Scott, Christiaan , Haga, Nobuhiko , Grunwald, Zvi, Cunto, Carmen L. De, Rocco, Maja Di , Delai, Patricia , Diecidue, Robert J. , Morhart, Rolf, Friedman, Clive, Zasloff, Michael , Shim, Jae‐Hyuck , Gao, Guangping , Pignolo, Robert J. , Micha, Dimitra , Shim, Jae-Hyuck , Vries, Teun J. de , Hsiao, Edward C. , Cunto, Carmen De , Madhuri, Vrisha , Cho, Tae‐Joon , Pals, Gerard , Kaplan, Frederick S.

Mayo Clinic

Human Gene Therapy | May 3, 2022 | Volume: 33 | Issue: 15-16 | Pages: 782-788

10.1089/hum.2022.023 | PMID 35502479 Get It

Fibrodysplasia ossificans progressiva (FOP) is a rare and devastating genetic disease, in which soft connective tissue is converted into heterotopic bone through an endochondral ossification process. Patients succumb early as they gradually become trapped in a second skeleton of heterotopic bone. Although the underlying genetic defect is long known, the inherent complexity of the disease has hindered the discovery of effective preventions and treatments. New developments in the gene therapy field have motivated its consideration as an attractive therapeutic option for FOP. However, the immune system's role in FOP activation and the as-yet unknown primary causative cell, are crucial issues which must be taken into account in the therapy design. While gene therapy offers a potential therapeutic solution, more knowledge about FOP is needed to enable its optimal and safe application.